The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.
Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.
A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.
Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.
Treatment with lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately 25% of women with HER2-positive breast cancer.
Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.
Limited radiotherapy effective after low-risk tumors are removed, but questions remain.
An exploration of the interaction between the protein produced by the common cancer-causing KRAS gene and the AGO2 protein may lead to the possibility of interrupting the KRAS-AGO2 interaction as a possible therapy.
Two distinct causes of HER2 activation in lung cancer were demonstrated in a recent study. These findings imply that HER2-positive lung cancer may need different targeted therapies to combat these related but possibly distinct diseases.
Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
The metabolism of pancreatic cancer cells is altered by the anticancer activity of CDK4/6 inhibitors. Researchers hope this biologic vulnerability could be exploited to treat pancreatic cancer.
Dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations have been suggested by the largest analysis of breast cancer cell function to date.
Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may halt disease progression in certain patients.
Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.
Lung cancers with KRAS-related gene mutations might benefit from a triple therapy regimen of 2 experimental drugs plus radiation therapy.
Palbociclib, a new oral treatment for certain types of breast cancer, demonstrates potential as a treatment for other types of cancer as well.
Researchers identified a protein that is essential for MYC to cause cancer in mouse models, and they believe, could be a target for anticancer therapy.
Mandatory tumor tissue specimens and associated analyses for clinical trial participation appear to be a significant barrier to clinical trial enrollment and may delay treatment.
The evolution of drug resistance in a patient with lung cancer was demonstrated in a recent case. In the case, molecular analysis of a metastatic lesion revealed resistance to a third targeted therapy; however, the new mutation restored tumor response to the first targeted therapy used.
Findings from a recently published study point to the enzyme casein kinase 1δ (CK1δ), a critical regulator of growth, as a novel and highly vulnerable therapeutic target in hard-to-treat subtypes of breast cancer.
Certain drugs currently used to treat breast, ovarian, and pancreatic cancers could also be used to treat certain gastric cancers with a particular genomic molecular fingerprint.
Researchers identified two new cancer-causing gene mutations that could lead to more targeted and effective treatments for certain lung and prostate cancers.
Genome sequencing database provides easy access to information on clinically important cancer gene mutationsSeptember 25, 2015
Researchers designed an online database, the Cancer Driver Log (CanDL) to help oncologists and other health care professionals identify key mutations that drive tumor growth in tissues.
Scientists have discovered that magnetic resonance imaging (MRI) scanners, normally used to produce images, can be used direct tumor therapies to specific target sites.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
New research has identified as few as nine genetic features would need to be tested to identify high-risk patients who might benefit from intensive myeloma treatment.
A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.
Targeted therapy for skin cancer is effective in patients with sonic hedgehog (SHH) subtype of medulloblastomaAugust 26, 2015
A targeted therapy already used to treat advanced skin cancer has also been found to be effective when used to treat the most common subtype of adult medulloblastoma.
A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by targeted treatment.
New research indicates that treating patients with esophageal cancer with proton therapy produces fewer toxic side effects than utilizing older radiation therapies.
- Cancer-related Neuropathy May Respond to Gene Therapy
- No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk Women
- A Protein Could Predict the Response to Immunotherapy in Metastatic Melanoma
- Atezolizumab Approved for Locally Advanced or Metastatic Urothelial Carcinoma
- Clinical Results Matches Development Locale With Subtype of Disease in Glioblastoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Initiating Palliative Care in the Emergency Department
- Implementing a Distress Screening Process for Cancer Patients
- New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening
- Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer
- Specific Lifestyle Factors Can Significantly Affect Cancer Mortality
- Biomarker Indicates Which Patients With Colorectal Cancer Will Respond to Cetuximab
- Herbal Remedies May Be an Overlooked Global Health Hazard
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|